Clinical Efficacy and Safety of K+ Binders for Treatment of Hyperkalemia
Sodium polystyrene sulphonate (SPS) was approved by the Food and Drug Association (FDA) for treatment of hyperkalemia in 1958. Rigorous randomized controlled trial efficacy and safety data for this drug are lacking since the FDA did not require significant clinical data for drug approval prior to 1962. In contrast, two newer K+ binders, sodium zirconium cyclosilicate and patiromer, have been evaluated in several clinical trials and have demonstrated consistent K+-lowering efficacy and favorable safety profiles. The results of key clinical trials leading to the approval of these drugs use will be described (Table 3 and Table 4).
Curr Opin Nephrol Hypertens. 2020;29(1):29-38. © 2020 Lippincott Williams & Wilkins